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INTRODUCTION
Drug hypersensitivity syndrome is a severe, idiosyncratic
multi-system reaction caused by drugs, defined by the clini-
cal triad of fever, rash and internal organ involvement (1). It
is potentially life-threatening with significant morbidity.
Drug hypersensitivity syndrome due to glycopeptide antibi-
otics, such as vancomycin or teicoplanin, is a rare phenome-
non. While cases of suspected drug hypersensitivity syndrome
due to vancomycin have been reported previously (2-4), only
one case of drug hypersensitivity syndrome due to teicoplanin
has been reported in literature (5). Here, we describe a patient
with vertebral osteomyelitis and an epidural abscess who
developed hypersensitivity syndrome to both vancomycin
and teicoplanin.
CASE REPORT
A 50-yr-old man with a long-standing history of low back
pain presented with rapidly increasing pain and mild fever
persisting for a month following the third session of acupunc-
ture. His medical history included alcohol-related Child-Pugh
class A liver cirrhosis. Examination at a local orthopedic clin-
ic revealed tenderness at the lumbar spine. His initial body
temperature was 37.5℃. Complete blood count was normal
except for mild anemia (Hgb 11.0 g/dL) and leucocytosis
(11.8×103/ L). The ESR value was 58 mm/hr. Blood chemi-
stries showed increased C-reactive protein (CRP) (2.3 mg/dL
[0-0.5]) and mild derangement in liver function (bilirubin 0.9
mg/dL [0.2-1.2], alkaline phosphatase 388 IU/L [30-115],
AST 95 IU/L [0-40], ALT 45 IU/L [0-40]). L-spine MRI
showed the possibility of infectious vertebral osteomyelitis
with epidural abscess extending to the paravertebral area. 
After blood was taken for culture, he was empirically start-
ed on vancomycin intravenously at a dose of 1 g every 12 hr.
Blood cultures were negative. His body temperature dropped
below 37℃ after the fifth day of vancomycin treatment. On
day 18 of vancomycin treatment, he presented with a gen-
eralized maculopapular rash and his body temperature rose
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A Case of Hypersensitivity Syndrome to Both Vancomycin and
Teicoplanin
Drug hypersensitivity syndrome to both vancomycin and teicoplanin has not been
previously reported. We describe here a 50-yr-old male patient with vertebral osteo-
myelitis and epidural abscess who developed hypersensitivity syndrome to both
vancomycin and teicoplanin. Skin rash, fever, eosinophilia, interstitial pneumonitis,
and interstitial nephritis developed following the administration of each drug, and
resolved after withdrawing the drugs and treating with high dose corticosteroids.
The vertebral osteomyelitis was successfully treated with 6-week course of linezol-
id without further complications. Skin patch tests for vancomycin and teicoplanin
was done 2 months after the recovery; a weak positive result for vancomycin (10%
aq.,+at D2 and +at D4 with erythema and vesicles; ICDRG scale), and a doubtful
result for teicoplanin (4% aq.-at D2 and±at D4 with macular erythema; ICDRG
scale). We present this case to alert clinicians to the hypersensitivity syndrome that
can result from vancomycin and teicoplanin, with possible cross-reactivity, which
could potentially be life-threatening.
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up to 39℃. The blood chemistry showed increased CRP
(12.1 mg/dL [0-10]) and creatinine (2.2 mg/dL [0.7-1.4])
level. The white blood cell count was 16.9×103/ L and the
eosinophil count was 1,605/ L. The ESR was 55 mm/hr.
Vancomycin was stopped and intravenous ceftriaxone was
started at a dose of 1 g every 8 hr for 2 days. Because he rema-
ined febrile and the skin rash persisted and desquamated, all
antibiotics were withdrawn. Gradually, skin rash improved
and he became afebrile. The follow-up L-spine MRI showed
slight improvement of the vertebral osteomyelitis and epidu-
ral abscess. Four days after discontinuing all the antibiotics,
he was started on teicoplanin intravenously at a dose of 600
mg every 48 hr. However, on the third day of teicoplanin
treatment, a generalized cutaneous maculopapular rash devel-
oped accompanied by respiratory and gastrointestinal symp-
toms; non-productive cough, dyspnea, wheezing, abdominal
pain, nausea and vomiting. Crackling sounds were heard on
both lung fields. The white blood cell count was 15.2×103/
L and the eosinophil count increased to 3,648/ L. The serum
creatinine level was elevated up to 4.4 mg/dL and the CRP
level was 12.85 mg/dL. The chest radiography and chest com-
puted tomography scan suggested the possibility of a hyper-
sensitivity pneumonitis. All drugs were stopped and he was
referred to our department. 
Under the diagnosis of drug hypersensitivity syndrome
with hypersensitivity pneumonitis and nephritis, methyl-
prednisolone was started with 30 mg every 6 hr. After 3 days
of the treatment, the serum creatinine decreased to 1.6 mg/dL
and the eosinophil count decreased to 136/ L. The respira-
tory and gastrointestinal symptoms disappeared, and skin
rash and fever improved. The L-spine MRI showed aggra-
vated osteomyelitis and paravertebral abscess. Endoscopic
surgery was done for curettage. Microscopic examination and
culture studies of the resected bony tissue were negative for
microorganisms. PCR study for Mycobacterium tuberculosis was
negative. After the surgery, linezolid was started at a dose of
600 mg every 12 hr. Prednisolone was slowly tapered over 2
weeks. The patient was successfully treated with 4 weeks of
intravenous and 2 weeks of oral linezolid without further com-
plications. 
The skin patch tests for vancomycin and teicoplanin was
done 2 months after the hypersensitivity syndrome resolved.
The patch tests showed a weak positive result for vancomycin
(10% aq.,+at D2 and +at D4 with erythema and vesicles;
ICDRG scale), and a doubtful result for teicoplanin (4% aq.
-at D2 and±at D4 with macular erythema; ICDRG scale).
Patch tests for ceftriaxone and 27 other control drugs showed
negative results. The patch tests with 10% aq. vancomycin
and 4% aq. teicoplanin were done in 20 control patients who
had experienced drug hypersensitivity to drugs other than
vancomycin and teicoplanin, and they all showed negative
results to vancomycin and teicoplanin.
DISCUSSION
Hypersensitivity syndrome, or drug rash with eosinophil-
ia and systemic symptoms (DRESS), is a well known find-
ing with anticonvulsants and sulfonamide drugs (6). Bocquet
and his group proposed a criteria for the diagnosis for DRESS
syndrome: cutaneous drug eruption, hematological abnor-
malities (eosinophilia more than 1.5×109/L or presence of
atypical lymphocytes) and systemic involvement (adenopa-
thies more than 2 cm in diameter or hepatitis or interstitial
nephritis or interstitial pneumonitis or carditis) (6, 7). The
patient presented here meets the criteria: skin rash resulting
in exfoliative dermatitis, eosinophilia, interstitial pneumonitis,
and possible interstitial nephritis suggested by azotemia.
Severe adverse drug reactions such as drug hypersensitivity
syndrome caused by vancomycin is a rare phenomenon with
only few cases reported in literature, despite its relatively more
frequent incidences of cutaneous hypersensitivity reactions
(2-4). Drug hypersensitivity syndrome due to teicoplanin
has been reported in only one case recently (5). The diagno-
sis was made on the basis of signs and symptoms associated
with the syndrome which rapidly resolved after withdrawal
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Fig. 1. Chemical structures of vancomycin and teicoplanin. The
core common to these molecules is shown in bold (Adapted from
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of the drug. Our patient had not only the hypersensitivity
syndrome to vancomycin, but also to teicoplanin. Improve-
ment of the maculopapular skin rash and pyrexia after dis-
continuation of vancomycin, worsening of the skin lesions
and newly developed respiratory and gastrointestinal symp-
toms after starting teicoplanin clearly suggest that both of
these drugs caused hypersensitivity syndrome. The symp-
toms and signs of hypersensitivity syndrome diminished
after removal of all antibiotics and starting treatment with
high dose corticosteroids. 
It has been reported on the possible allergic cross-reactivity
between vancomycin and teicoplanin in a few previous reports;
maculopapular rash (8), erythrodermic rash (9), vasculitis
(10), and drug fever after vancomycin induced red man syn-
drome (11). Only one report showed positive patch tests for
both vancomycin and teicoplanin in a patient with hyper-
sensitivity to vancomycin. However, teicoplanin was not used
and its potential hypersensitivity was not determined (12).
Our case clinically suggested a possible cross-reactivity bet-
ween these glycopeptide antibiotics in the hypersensitivity
syndrome. The reason for this cross-reactivity is unclear, but
it may well be due to the fact that both of these antibiotics
share the similar glycopeptide structure (Fig. 1). 
Previous reports used 4% diluted teicoplanin (12) and 0.05-
5% diluted vancomycin in the patch tests (12, 13). However,
the optimal concentration of vancomycin in the patch tests
has not yet been established. We used 10% diluted vanco-
mycin in the patch test because 10% dilution is the most
commonly used concentration used in drug patch tests. We
have done the patch tests with 10% aq. vancomycin and 4%
aq. teicoplanin in 20 control patients who had not experienced
any type of hypersensitivity reaction against vancomycin or
teicoplanin, and they all showed negative results. Our expe-
rience supports that 10% diluted vancomycin can be used
in patch tests.
Linezolid is reported to be an effective agent in treating
patients with osteomyelitis due to linezolid-susceptible Gram
positive bacteria, who are intolerant to vancomycin or have
resistant Gram-positive infection (14). Despite the absence
of identifiable microorganisms in our patient, empirical tar-
geting of Gram (+) bacteria and the use of linezolid resulted
in successful treatment of the vertebral osteomyelitis and
epidural abscess.
We present this case to alert clinicians to the hypersensitivity
syndrome that can result from both vancomycin and teico-
planin, which may present as a life-threatening emergency.
Furthermore, we suggest the possible cross-reactivity of these
glycopeptide antibiotics in the hypersensitivity syndrome and
show that linezolid is an effective and safe alternative.
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